Clinical Trial Update: Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating PEP02, irinotecan, or docetaxel in gastric or gastroesophageal junction adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)
• PEP02

Snippet

Sponsor: PharmaEngine | Conditions: Stomach Neoplasms, Esophageal Neoplasms | Phase 2 | Status: COMPLETED